Bosentan Improves Quality Of Life For Patients With Pulmonary Hypertension

Main Category: Hypertension
Also Included In: Cardiovascular / Cardiology;  Respiratory / Asthma
Article Date: 20 Jul 2008 - 0:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Recent studies have shown that bosentan therapy greatly improves the quality of life for patients with pulmonary arterial hypertension (PAH). According to a study in Respirology published by Wiley-Blackwell, treatments with oral Bosentan reduces resistance in blood flow - allowing the heart and lungs to work more efficiently and in turn, enables patients to increase exercise capacity and quality of life.

PAH is a syndrome where one experiences continuous high blood pressure in the pulmonary arteries, or the blood vessels supplying blood to the lungs. In PAH, the heart has to work very hard to pump against the high resistance and eventually weakens. When it loses the ability to pump enough blood, heart failure occurs and often death.

Although there is no cure for PAH, there are treatments that are beneficial to the patients. Bosentan is an oral endothelin receptor antagonist that significantly improves functional status, increase blood flow and survival of patients.

Lead author, Mr. Geoff Strange says, "Quality of life is an important consideration in the treatment of diseases such as PAH, in which prognosis is typically poor. In such chronic diseases, patients view improvement in quality of life as an important measure of treatment success."

After three months of Bosentan treatment, patients showed improvements in their exercise capacity in the six minute walk test (6MWT), as well as domains that measured quality of life. Although the assessment of quality of life and 6MWT provides complementary data at individual time points, they did not correlate over time as a response to therapy.

Professor Eli Gabbay, from the Royal Perth Hospital and The University of Western Australia adds, "While quality of life and 6MWT data were parallel at individual points, quality of life may improve on Bosentan therapy independent of the improvements in 6MWT. The quality of life domains should be specifically assessed to improve the monitoring of patients with PAH as changes in quality of life cannot be extrapolated from routine clinical variables."

"Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in six-minute walk test and quality of life"
Respirology (Vol. 13, Issue 5).
Click here to view abstract online

About Respirology

Respirology is a journal of international standing, publishing peer-reviewed articles of scientific excellence in clinical and experimental respiratory biology and disease and its related fields of research including thoracic surgery, internal medicine, immunology, intensive and critical care, epidemiology, cell and molecular biology, pathology, pharmacology and physiology.

About Wiley-Blackwell

Wiley-Blackwell was formed in February 2007 as a result of the acquisition of Blackwell Publishing Ltd. by John Wiley & Sons, Inc., and its merger with Wiley's Scientific, Technical, and Medical business. Together, the companies have created a global publishing business with deep strength in every major academic and professional field. Wiley-Blackwell publishes approximately 1,400 scholarly peer-reviewed journals and an extensive collection of books with global appeal. For more information on Wiley-Blackwell, please visit www.blackwellpublishing.com or http://interscience.wiley.com.

About Wiley

Founded in 1807, John Wiley & Sons, Inc. has been a valued source of information and understanding for 200 years, helping people around the world meet their needs and fulfill their aspirations. Since 1901, Wiley and its acquired companies have published the works of more than 350 Nobel laureates in all categories: Literature, Economics, Physiology/Medicine, Chemistry and Peace. Our core businesses include scientific, technical, medical and scholarly journals, encyclopedias, books, and online products and services; professional/trade publishes books, subscription products, training materials, and online applications and websites; and educational materials for undergraduate and graduate students and lifelong learners. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company is listed on the New York Stock Exchange under the symbols JWa and JWb.

The Company's Web site can be accessed at http://www.wiley.com.